ZA200601852B - Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents - Google Patents
Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents Download PDFInfo
- Publication number
- ZA200601852B ZA200601852B ZA200601852A ZA200601852A ZA200601852B ZA 200601852 B ZA200601852 B ZA 200601852B ZA 200601852 A ZA200601852 A ZA 200601852A ZA 200601852 A ZA200601852 A ZA 200601852A ZA 200601852 B ZA200601852 B ZA 200601852B
- Authority
- ZA
- South Africa
- Prior art keywords
- defibrotide
- mammalian
- affected
- active ingredient
- tumour
- Prior art date
Links
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960004120 defibrotide Drugs 0.000 title claims abstract description 63
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 12
- 238000009472 formulation Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000009471 action Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 229960001924 melphalan Drugs 0.000 claims description 10
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 10
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 claims description 7
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims description 7
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 claims description 7
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- -1 monocrotalirze Chemical compound 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 5
- 229960001196 thiotepa Drugs 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 208000012766 Growth delay Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002634 anti-blastic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001714A ITMI20031714A1 (it) | 2003-09-05 | 2003-09-05 | Formazioni ad azione antitumorale. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601852B true ZA200601852B (en) | 2007-06-27 |
Family
ID=37064585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601852A ZA200601852B (en) | 2003-09-05 | 2004-08-27 | Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8551967B2 (hr) |
| EP (1) | EP1660100B1 (hr) |
| JP (1) | JP4671962B2 (hr) |
| KR (1) | KR20060061367A (hr) |
| CN (1) | CN100490820C (hr) |
| AT (1) | ATE399558T1 (hr) |
| AU (1) | AU2004269896B2 (hr) |
| BR (1) | BRPI0414114A (hr) |
| CA (1) | CA2537226C (hr) |
| DE (1) | DE602004014787D1 (hr) |
| DK (1) | DK1660100T3 (hr) |
| ES (1) | ES2308223T3 (hr) |
| IL (1) | IL173785A0 (hr) |
| IS (1) | IS8334A (hr) |
| IT (1) | ITMI20031714A1 (hr) |
| MX (1) | MXPA06002489A (hr) |
| NO (1) | NO20061402L (hr) |
| PT (1) | PT1660100E (hr) |
| RS (1) | RS20060154A (hr) |
| RU (1) | RU2348413C2 (hr) |
| UA (1) | UA83500C2 (hr) |
| WO (1) | WO2005023273A1 (hr) |
| ZA (1) | ZA200601852B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008531647A (ja) * | 2005-03-03 | 2008-08-14 | ゲンチウム エスピーエー | 抗腫瘍作用を有する製剤 |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| AU2010363814B2 (en) | 2010-11-12 | 2016-05-19 | Gentium S.R.L. | Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD). |
| KR20150044877A (ko) | 2012-06-22 | 2015-04-27 | 젠티엄 에스피에이 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (en) * | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| US10380734B2 (en) * | 2017-02-27 | 2019-08-13 | Aniket Bharat Parikh | System, method and computer program product for security analysis of jewelry items |
| CN111132663A (zh) * | 2017-08-03 | 2020-05-08 | 爵士制药爱尔兰有限公司 | 包含高浓度核酸的制剂 |
| MX2020010689A (es) | 2018-04-12 | 2021-01-20 | Jazz Pharmaceuticals Inc | Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion. |
| US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| EP4110287A1 (en) | 2020-02-28 | 2023-01-04 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| WO2022234101A1 (en) | 2021-05-06 | 2022-11-10 | Jazz Pharmaceuticals Ireland Limited | Defibrotide for the treatment and prevention of acute respiratory distress syndrome |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US4853221A (en) * | 1980-11-13 | 1989-08-01 | Warner-Lambert Company | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer |
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
| DE9202745U1 (de) | 1992-03-02 | 1992-04-30 | Howmedica Gmbh, 2314 Schoenkirchen | Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| AU8125098A (en) | 1997-05-30 | 1998-12-30 | Mcgill University | Dna methyltransferase genomic sequences and antisense oligonucleotides |
| US6177545B1 (en) | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
| DE19740384A1 (de) | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| IL146872A0 (en) * | 1999-06-03 | 2002-08-14 | Methods and compositions for modulating cell proliferation and cell death | |
| HUP0700079A2 (en) * | 2000-12-29 | 2007-05-02 | Savient Pharmaceuticals | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US6770753B2 (en) | 2001-07-05 | 2004-08-03 | The Trustees Of Columbia University In The City Of New York | Phosphorothioate antisense heparanase oligonucleotides |
| WO2003027313A2 (en) | 2001-09-24 | 2003-04-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
| RS102504A (en) * | 2002-05-31 | 2006-12-15 | Universitat Regensburg | Method for the protection of endothelial and epithelial cells during chemotherapy |
| CA2491363A1 (en) * | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| CA2501719C (en) | 2002-08-06 | 2013-02-05 | Toray Industries, Inc. | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| JP2008531647A (ja) | 2005-03-03 | 2008-08-14 | ゲンチウム エスピーエー | 抗腫瘍作用を有する製剤 |
| EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
-
2003
- 2003-09-05 IT IT001714A patent/ITMI20031714A1/it unknown
-
2004
- 2004-08-27 DK DK04764686T patent/DK1660100T3/da active
- 2004-08-27 RS YUP-2006/0154A patent/RS20060154A/sr unknown
- 2004-08-27 CN CNB2004800253315A patent/CN100490820C/zh not_active Expired - Fee Related
- 2004-08-27 AU AU2004269896A patent/AU2004269896B2/en not_active Ceased
- 2004-08-27 EP EP04764686A patent/EP1660100B1/en not_active Expired - Lifetime
- 2004-08-27 RU RU2006109210/15A patent/RU2348413C2/ru not_active IP Right Cessation
- 2004-08-27 KR KR1020067004451A patent/KR20060061367A/ko not_active Application Discontinuation
- 2004-08-27 MX MXPA06002489A patent/MXPA06002489A/es active IP Right Grant
- 2004-08-27 AT AT04764686T patent/ATE399558T1/de active
- 2004-08-27 ZA ZA200601852A patent/ZA200601852B/en unknown
- 2004-08-27 UA UAA200602374A patent/UA83500C2/uk unknown
- 2004-08-27 CA CA2537226A patent/CA2537226C/en not_active Expired - Fee Related
- 2004-08-27 DE DE602004014787T patent/DE602004014787D1/de not_active Expired - Lifetime
- 2004-08-27 JP JP2006525096A patent/JP4671962B2/ja not_active Expired - Fee Related
- 2004-08-27 ES ES04764686T patent/ES2308223T3/es not_active Expired - Lifetime
- 2004-08-27 PT PT04764686T patent/PT1660100E/pt unknown
- 2004-08-27 BR BRPI0414114-8A patent/BRPI0414114A/pt not_active IP Right Cessation
- 2004-08-27 WO PCT/EP2004/009723 patent/WO2005023273A1/en active IP Right Grant
-
2006
- 2006-02-16 IL IL173785A patent/IL173785A0/en unknown
- 2006-02-28 IS IS8334A patent/IS8334A/is unknown
- 2006-03-02 US US11/366,243 patent/US8551967B2/en not_active Expired - Fee Related
- 2006-03-28 NO NO20061402A patent/NO20061402L/no not_active Application Discontinuation
-
2013
- 2013-09-06 US US14/019,674 patent/US20140005256A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2537226C (en) | 2016-05-03 |
| DK1660100T3 (da) | 2008-11-10 |
| RU2348413C2 (ru) | 2009-03-10 |
| ES2308223T3 (es) | 2008-12-01 |
| RS20060154A (en) | 2008-08-07 |
| US20140005256A1 (en) | 2014-01-02 |
| KR20060061367A (ko) | 2006-06-07 |
| BRPI0414114A (pt) | 2006-10-31 |
| RU2006109210A (ru) | 2007-10-10 |
| EP1660100A1 (en) | 2006-05-31 |
| WO2005023273A1 (en) | 2005-03-17 |
| NO20061402L (no) | 2006-03-28 |
| AU2004269896B2 (en) | 2009-11-19 |
| PT1660100E (pt) | 2008-10-14 |
| CN1845746A (zh) | 2006-10-11 |
| CA2537226A1 (en) | 2005-03-17 |
| JP4671962B2 (ja) | 2011-04-20 |
| CN100490820C (zh) | 2009-05-27 |
| AU2004269896A1 (en) | 2005-03-17 |
| EP1660100B1 (en) | 2008-07-02 |
| IS8334A (is) | 2006-02-28 |
| US8551967B2 (en) | 2013-10-08 |
| ATE399558T1 (de) | 2008-07-15 |
| MXPA06002489A (es) | 2006-06-20 |
| ITMI20031714A1 (it) | 2005-03-06 |
| DE602004014787D1 (de) | 2008-08-14 |
| IL173785A0 (en) | 2006-07-05 |
| US20060211646A1 (en) | 2006-09-21 |
| UA83500C2 (uk) | 2008-07-25 |
| JP2007504194A (ja) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140005256A1 (en) | Formulations with anti-tumour action | |
| Gorelik et al. | Role of NK cells in the control of metastatic spread and growth of tumor cells in mice | |
| TWI359029B (en) | Liposomes useful for drug delivery | |
| US6906048B2 (en) | N-acetylcolchinol-O-phosphate combination therapies with vascular damaging activity | |
| EP0114589A1 (en) | Inhibition of angiogenesis | |
| AU2001242581A1 (en) | Combination therapies with vascular damaging activity | |
| US11351190B2 (en) | Composition for treating tissue lesions | |
| CN111343984A (zh) | 包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物 | |
| CN109498627A (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| JPH10511677A (ja) | イノシトール三燐酸の薬剤調製への使用 | |
| FR2910813A1 (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| AU2016330332A1 (en) | An anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof | |
| CZ20023231A3 (cs) | Farmaceutické prostředky obsahující činidla poąkozující cévy | |
| JPH07506584A (ja) | 血小板減少症治療における外因性グリコサミノグリカン類または誘導体の利用 | |
| Li et al. | Overcoming neutrophil-induced immunosuppression in postoperative cancer therapy: Combined sialic acid-modified liposomes with scaffold-based vaccines | |
| US20220339175A1 (en) | Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate Cancer | |
| RU2268729C2 (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды | |
| JPH0460093B2 (hr) | ||
| ZA200207114B (en) | Combination therapies with vascular damaging activity. |